Handedness matters: Chiral molecules exist in two versions that are mirror images of each other, like human hands. Enzyme catalysis can help to produce one of these symmetryrelated versions selectively. (Photo: © age fotostock / SuperStock.)
Given the importance of catalysts both for life and for technology, attempts to adapt or mimic natural enzymes for technological purposes have been made for decades. With the knowledge of crystal structures that have been coming in at everfaster rates since the 1960s, researchers have been able to tweak the geometry of active sites to alter an enzyme's substrate specificity.
A bigger challenge lies in the reactions that nature simply doesn't use, but chemists do, including the Diels-Alder ring formation with its highly elegant dance of six electrons. In the early 1990s, several laboratories developed antibodies against analogues of the transition state of the target reaction. This approach is based on the idea that stabilising the transition state by binding it to the antibody will lower its energy, thus bringing down the activation energy of the reaction.
A few catalytic antibodies, also known as abzymes, were successfully produced, including two catalysing the Diels-Alder reaction. However, the approach turned out to have serious limitations, which include the difficulty of expressing antibodies in bacteria, along with structural constraints posed by the standard immunoglobulin architecture and functional ones related to the focus on the recognition of the transition state.
Thus, abzymes ultimately failed to satisfy the ambitions of enzyme designers, and attention returned to the question of how one could create a proper enzyme that doesn't yet exist in nature.
Feature
Designing Diels-Alderase Building on their experience in protein design algorithms (Curr. Biol. (2012) 22, R35-R38), David Baker and his group at the University of Washington at Seattle embarked on designing an enzyme for the Diels-Alder reaction from first principles (Science (2010) 329, 309-313) . Using the widely studied quantum-mechanical mechanism of the reaction, they identified ideal positions for a hydrogen bond acceptor to bind the diene (an alkene with two double bonds separated by a single bond) and for a hydrogen bond donor to interact with the dienophile (the alkene that reacts with the diene). Calculations predicted that these two interactions should narrow the energy gap between the molecular orbitals relevant for the reaction, thereby lowering the activation energy.
With the resulting constraints for the active site structure, Baker and colleagues set their protein design algorithm Rosetta to produce proteins sequences containing such a site. They chose 84 of the designs for experimental tests involving synthesis of the relevant genes and expression in E. coli. Of these, 50 proteins could be successfully expressed and purified. Only two of the designs actually displayed Diels-Alderase activity when tested with the substrates on which the design was based.
Based on these two successful designs, the researchers could improve the catalytic activity by mutating amino acids surrounding the active site. The most successful of the resulting variants turned out to have a 97% selectivity for the desired product, which is one of eight possible isomeric forms, and which in the uncatalysed reaction would only represent less than half of the product yield.
As Baker and colleagues point out in their paper, having an enzyme that is active in a new kind of chemical reaction is only the beginning of new endeavours. Established methods of protein engineering as well as directed evolution (see below) can be applied to vary parameters, including the substrate specificity and the efficiency of the enzyme.
With their high selectivity and specificity especially in chiral reactions, natural enzymes are superior to all man-made catalysts. There are many reactions of interest, however, that just don't occur in their repertoire. With a range of innovative approaches, scientists are now able to create enzymes with entirely new activities. Michael Gross reports.
This process may eventually lead to a whole family of novel enzymes that will be natural in their biological structure but will perform activities wholly unprecedented in nature.
Conferring chirality
Last year, researchers used a different approach to create a novel metallo-enzyme, which can lend chiral specificity to a kind of ligand widely used in organic chemistry. The groups of Thomas Ward from the University of Basel, Switzerland, and Tomislav Rovis from Colorado State University at Fort Collins, US, exploited the natural affinity between the protein streptavidin and its ligand biotin, linking a cyclopentadienyl ligand to the biotin via an amide bond (Science (2012) 338, 500-503). The cyclopentadienyl anion is an aromatic, electron-rich ring compound which readily associates with transition metal ions, e.g. with iron to form ferrocene. Its derivatives are widely used in metal-organic chemistry and catalysis, but it is difficult to turn this highly symmetric compound into something that could confer chirality in a catalysed reaction.
Ward and Rovis studied a reaction in which a normally inert carbon-hydrogen bond in a benzene derivative is activated such that a second ring can connect that carbon atom to a side chain already attached to the benzene. As a model substrate they used benzhydroxamic acid (Ph-CO-NH-OH), with methylacrylate as the reaction partner that binds to the activated site of the benzene and closes the ring. In the reaction, the pair of carbon atoms joined by a double bond in the methylacrylate can insert itself into the new ring in two different orientations (regioselectivity), and the one closer to the ester group will become a chiral centre, leading to a total of four possible stereoisomers.
Complexes of rhodium liganded with a cyclopentadienyl derivative on one side and chloride ions on the other are known to catalyse this reaction. The mechanism requires the rhodium to keep the cyclopentadienyl ring and to use all three coordination sites opposite to it, such that there is no space where one could introduce a chiral ligand to guide the stereochemistry of the reaction.
By coupling the cyclopentadienyl ring to biotin, which in turn naturally binds to the protein streptavidin, the researchers created an artificial metal enzyme for this reaction in the hope that the chiral environment of the protein would induce stereochemical selectivity in the reaction, which otherwise leads to a nearly balanced racemate.
First experiments with the new construct gave only traces of the desired product. Modelling the active site, the researchers identified two amino acid side chains of streptavidin that are located close to the metal and might have an influence on the reaction. Systematically replacing these with acidic side chains, they found that a variant with an aspartate residue in position 121 achieves good reaction yields. "Engineering this carboxylate residue proved critical as it significantly accelerated the rate-determining C-H deprotonation step," explains Ward.
The researchers then mutagenised the other amino acid residue close to the site in a bid to improve stereoselectivity. In position 112, introduction of aromatic side chains led to both improved turnover and enantiomeric purity of the product. Further studies revealed that the four rhodium complexes incorporated into a streptavidin tetramer act completely independently and with the same performance parameters.
As the new enzyme closes a ring next to a benzene ring, it could be categorised as a benzannulase. In a mixture of MOPS buffer and methanol, it can also activate certain substituted variants of the original substrate as well as a bicyclic one (i.e. a naphthalene derivative).
Triangulation tricks
Ring compounds of just three carbon atoms (cyclopropane compounds) are highly strained and therefore unstable. No wonder that they are rarely found in nature (although plants use a cyclopropane amino acid as a precursor for the Docking site: A model of the 'active site' where a catalytic rhodium (orange) cyclopentadienyl complex bound to biotin would dock in the streptavidin structure. Of the amino acid residues drawn as stick models, residues 112 (shown just above the rhodium complex) and 121 (below) have proven crucial to the enzymatic activity of the artificial construct ( Figure  reproduced with permission from Hyster et al. Science (2012) 338,500-503.) production of the hormone ethylene), while organic chemists consider them an interesting challenge.
To create an artificial enzyme to meet this challenge, the group of Frances Arnold at the California Institute of Technology at Pasadena, US, started from a large and versatile family of enzymes, namely the cytochrome P450 enzymes (Science (2013) 339, 307-310) . Behind the bewildering variety of chemical reactions catalysed by this large family of proteins stands a very simple chemical reason. These so-called mono-oxygenases have a common way of reducing one of the two atoms in an oxygen molecule to make water. With the remaining oxygen atom, evolution apparently allowed them to do whatever they wanted, such that today there are thousands of very different redox reactions catalysed by these enzymes, which are used, for instance, in hormone synthesis, processing of fatty acids, and decomposition of organic substances.
Some of these reactions lead to a reactive species geometrically similar to cyclopropane, but with an oxygen taking the place of one of the carbon atoms in the triangle, known as an epoxide. Specifically, these enzymes activate oxygen by coordinating the single atom to a haem-iron cofactor, from which the oxygen is transferred to a carboncarbon double bond, with which it forms the epoxide.
Arnold and her coworkers had already studied variants of one such cytochrome P450 enzyme, namely CYP102A1 from Bacillus megaterium, in great detail and accumulated thousands of variants of it, when they embarked on a radical change to the catalysed reaction. If they could replace the oxene ligand on the haem iron with the electronically equivalent carbene, they reckoned they should be able to transfer this to an alkene and obtain a cyclopropane compound. Moreover, this reaction breaks the symmetry of the alkene and creates two new chiral centres, as long as each side of the C=C double bond carries two different substituents. With the chiral environment of a re-engineered cytochrome P450 enzyme, the researchers hoped they might be able to make this reaction selective for one of the four possible stereoisomers. (The non-hydrogen substituents can be arranged on the same side of the triangle plane (cis) or on opposite sides (trans), and each of these versions comes as a pair of enantiomers (mirror images).)
Initial experiments showed that wild-type CYP102A1 as well as some other P450 enzymes showed a modest ability to produce cyclopropane compounds from model substrates (styrene as the alkene compound, and ethyl diazo acetate as the carbene precursor). Screening their library of variants systematically, Arnold and colleagues identified 92 diverse candidates which they tested in detail. Out of a final shortlist of ten variants, they found that five were more active than the wild type and showed an interesting range of stereoselectivities, with up to 95% enantioselectivity. From these, the researchers picked one variant for detailed investigation of the enzyme reaction and further mutagenesis. Their results, the authors conclude, "suggest that this approach will be useful for other synthetically important transformations for which biological counterparts do not yet exist."
Organic chemistry has no shortage of reactions lacking enzyme support. "Among the synthetically important reactions for which no natural enzymes exist, one should mention C-C crosscoupling reactions as well as olefin metathesis. Both these reaction classes were awarded Nobel prizes in the past few years," says Ward, referring to the inventions of Nobel laureates Richard Heck, Ei-ichi Negishi, and Akira Suzuki (2010), and of Yves Chauvin, Robert Grubbs, and Richard Schrock (2005) . "With synthetic biology applications in mind, creating artificial enzymes for these reactions would open fascinating perspectives to complement metabolic pathways with these abiotic reactions."
Pedro Coelho, first author of the cyclopropane paper, nominated the same two types of reactions, and also mentioned the Wittig reaction (converting an aldehyde or ketone into an alkene, Nobel prize 1979).
Screening systematically
Once scientists have succeeded in producing a novel enzyme, Natural catalyst: A crystal structure of the enzyme CYP102A1, of which researchers have created thousands of variants, including some that produce cyclopropane compounds instead of epoxides. (Image courtesy of Eric M. Brustad and generated in Pymol (The PyMOL Molecular Graphics System, Version 1.5.0.4 Schrödinger, LLC.).)
